MPO’s Most-Read Stories This Week—April 2

It was a week of firsts.

Fresenius Kabi’s new relationship with Ivenix, the FDA’s approval of original devices from Cutera and Staar Surgical, and initial patient implants in Medtronic’s TITAN2 pivotal study drove MPO website traffic over the last seven days.   

Fresenius is shelling out $240 million in up front and milestone payments for Ivenix, developer of a technologically advanced infusion system that includes a large volume pump (LVP) with administration sets, infusion management software tools, applications, and analytics. The system is designed to minimize infusion-related errors and lower total cost of ownership. Fresenius Kabi also agreed to acquire a 55 percent stake in biopharma company mAbxience for 495 million Euros in upfront and milestone payments. Both deals are expected to close by the middle of this year.

Also generating page views was the FDA approvls of Cutera’s AviClear, an energy-based device to treat mild, moderate, and severe acne, and implantable eye lens and companion delivery systems from STAAR Surgical. The AviClear laser treatment’s trials demonstrated shorter, less intense, and more infrequent future breakout episodes. Clearance results continued to improve over time and no pain mitigation was needed. AviClear resolves acne by selectively targeting sebocytes and suppressing sebum production.

STAAR Surgical’s EVO/EVO+ Visian Implantable Collamer lens (EVO) corrects myopia and myopia with astigmatism. EVOs are inserted in the eye’s posterior chamber behind the iris and in front of the natural crystalline lens. EVO is a lens-based alternative for refractive error correction/reduction for people using glasses or contact lenses for distance vision correction.

Finally, Medtronic annoounced the first patient implants in its TITAN2 pivotal study, which is evaluating the firm’s investigational tibial neuromodulation (TNM) device for overactive bladder (OAB). The minimally invasive technology stimulates the posterior tibial nerve, transmitting electrical impulses that regulate the bladder’s neural activity.
  

1. Fresenius Kabi to Buy Ivenix for $240M

2. 4 Steps Toward Efficient Upgrading of Ultrasonic Welding Systems in Medical Applications

3. FDA OKs Cutera’s AviClear Acne Device

4. First Implants for Medtronic’s Tibial Neuromodulation for OAB

5. FDA Approves STAAR Surgical’s EVO Visian Implantable Collamer Lenses